Company / Cash & Equivalents
RAPT Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$169.7M
FY2024
5-year range
$24.0M / $169.7M
FY2020-FY2024
Trend
+257.5%
vs FY2023
Sector context
#103 of 208
Health Care
What the data says
Cash & Equivalents changed +258% YoY in FY2024, a notable deviation from the 6-year average annual change of +49%.
Based on SEC 10-K filings.
$170M in FY2024 with a 5-year CAGR of +17.0%.
Improved from $39M to $170M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +91.9%
- 5-Year CAGR
- +17.0%
- 10-Year CAGR
- -
Sector benchmark
#103 of 208 in Health CareTop 50% of 208This company $169.7M Sector average $694.3M
▼
-75.6% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +17.0%, indicating consistent growth.
- In FY2024, cash & equivalents increased 257.5% year-over-year.
- Ranks #103 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $169.7M | +257.5% |
| FY2023 | $47.5M | +21.9% |
| FY2022 | $38.9M | +62.1% |
| FY2021 | $24.0M | -3.6% |
| FY2020 | $24.9M | -67.8% |
| FY2019 | $77.4M | +21.3% |
| FY2018 | $63.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026